About US
Contact us
-
BMS’ Opdivo fails in Phase III glioblastoma trialBristol-Myers Squibb (BMS) has announced that its immunotherapy drug Opdivo (nivolumab) has failed to meet its primary endpoint of overall survival (OS) in Phase III CheckMate-498 trial. In this rand2019/5/13
-
Roche’s Ocrevus to be available on NHS EnglandNational Health Service (NHS) England has entered a deal with Roche to make the Swiss drugmaker’s Ocrevus (ocrelizumab) medicine available at a lower price for routine use. Ocrevus is indicated to tr2019/5/13
-
Pfizer to purchase biotech firm Therachon for up to $810mPfizer has agreed to acquire Swiss biotechnology firm Therachon for a total consideration of $810mto support its rare disease portfolio. The deal involves an upfront payment of$340m and a further $472019/5/10
-
Takeda to divest dry eye drug to Novartis in $5.3bn dealTakeda Pharmaceutical has signed an agreement to sell its Xiidra 5% drug to Novartis for a total consideration of up to $5.3bn. Xiidra is an anti-inflammatory medicine indicated to treat the symptoms2019/5/10
-
Sanofi gets EC approval for Dupixent to treat severe asthmaSanofi’s Dupixent has been approved by the European Commission (EC) as an add-on maintenance treatment for severe asthma in adults and adolescents. The indication includes patients with Type 2 inflam2019/5/9
-
FDA approves paediatric LEMS drugThe US Food and Drug Administration (FDA) has approved Jacobus Pharmaceutical’s Ruzurgi (amifampridine) as a treatment for Lambert-Eaton myasthenic syndrome (LEMS). Ruzurgi is one of the first LEMS d2019/5/9
-
Bicycle and DDF collaborate on drug development for CNS conditionsUK-headquartered Bicycle Therapeutics and venture capital fund Dementia Discovery Fund (DDF) have entered into a collaboration to use the former’s bicyclic peptide technology to identify new targets2019/5/8
-
FDA approves Pfizer’s drugs for transthyretin amyloid cardiomyopathyThe US Food and Drug Administration (FDA) has approved Pfizer’s Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) to treat cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM).2019/5/8
-
GSK chases Trelegy asthma nod with mixed phase 3 resultsWith generics attacking Advair, GlaxoSmithKline has talked up prospects for 3-in-1 respiratory med Trelegy. Now, the company has data in hand that could help it move into the asthma arena—though it's2019/5/7
-
Novo's fast-launching Ozempic puts Lilly on notice—and its GLP-1 pill is on its wayNovo Nordisk has been fighting head-to-head with Eli Lilly for share in the GLP-1 diabetes market—and losing, as Lilly's weekly Trulicity stole scripts from Novo's daily Victoza. But now that Novo ha2019/5/7